Similar Papers

Paper Title
Journal
Date
Author
Long-Term Safety, Tolerability, And Efficacy of Efgartigimod in Patients with Generalized Myasthenia Gravis: Concluding Analyses from the ADAPT+ Study (S5.006)
Mamatha Pasnoor ... Caroline T’Joen
Neurology | VOL. 100
Mamatha Pasnoor, et. al.Mamatha Pasnoor ... Caroline T’Joen
25 Apr 2023
Efgartigimod Demonstrates Consistent Improvements in Generalized Myasthenia Gravis Patients of Shorter Disease Duration (P1-5.015)
Vera Bril ... James Howard
Neurology | VOL. 100
Vera Bril, et. al.Vera Bril ... James Howard
25 Apr 2023
Achievement of Improved Post-Intervention Status in Patients with Generalized Myasthenia Gravis Treated with Ravulizumab during the CHAMPION MG Study (S5.008)
Srikanth Muppidi ... James Howard
Neurology | VOL. 100
Srikanth Muppidi, et. al.Srikanth Muppidi ... James Howard
25 Apr 2023
Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis (P1-5.017)
George Li ... Tuan Vu
Neurology | VOL. 100
George Li, et. al.George Li ... Tuan Vu
25 Apr 2023
View more papers

More From: Neurology

Paper Title
Journal
Date
Author
Reader Response: Distribution of Silent Cerebral Infarcts in Adults With Sickle Cell Disease
Calixto Machado
Neurology | VOL. -
Calixto MachadoCalixto Machado
28 Jan 2025
Brain Hypertrophy in Patients With Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis and Its Clinical Correlates
Richard Zubal ... Marian Galovic
Neurology | VOL. 104
Richard Zubal, et. al.Richard Zubal ... Marian Galovic
28 Jan 2025
Reader Response: Wall-Eyed Bilateral Internuclear Ophthalmoplegia Variant Syndrome Caused by Isolated Left Thalamic Infarction.
Eric R Eggenberger
Neurology | VOL. 104
Eric R EggenbergerEric R Eggenberger
28 Jan 2025
Editors' Note: Distribution of Silent Cerebral Infarcts in Adults With Sickle Cell Disease
Aravind Ganesh ... Steven L Galetta
Neurology | VOL. -
Aravind Ganesh, et. al.Aravind Ganesh ... Steven L Galetta
28 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.